As of 2026-03-26, the EV/EBITDA ratio of Inovio Pharmaceuticals Inc (INO) is -0.70. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. INO's latest enterprise value is 61.52 mil USD. INO's TTM EBITDA according to its financial statements is -88.05 mil USD. Dividing these 2 quantities gives us the above INO EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 14.2x - 19.2x | 16.3x |
| Forward P/E multiples | 19.2x - 25.2x | 21.3x |
| Fair Price | (24.01) - (23.94) | (23.45) |
| Upside | -1659.3% - -1654.3% | -1622.7% |
| Date | EV/EBITDA |
| 2026-03-19 | -0.78 |
| 2026-03-18 | -0.79 |
| 2026-03-17 | -0.81 |
| 2026-03-16 | -0.77 |
| 2026-03-13 | -0.79 |
| 2026-03-12 | -0.81 |
| 2026-03-11 | -0.82 |
| 2026-03-10 | -0.85 |
| 2026-03-09 | -0.85 |
| 2026-03-06 | -0.85 |
| 2026-03-05 | -0.81 |
| 2026-03-04 | -0.85 |
| 2026-03-03 | -0.81 |
| 2026-03-02 | -0.85 |
| 2026-02-27 | -0.91 |
| 2026-02-26 | -0.89 |
| 2026-02-25 | -0.94 |
| 2026-02-24 | -0.97 |
| 2026-02-23 | -0.91 |
| 2026-02-20 | -0.85 |
| 2026-02-19 | -0.84 |
| 2026-02-18 | -0.80 |
| 2026-02-17 | -0.77 |
| 2026-02-13 | -0.75 |
| 2026-02-12 | -0.73 |
| 2026-02-11 | -0.75 |
| 2026-02-10 | -0.82 |
| 2026-02-09 | -0.82 |
| 2026-02-06 | -0.79 |
| 2026-02-05 | -0.71 |
| 2026-02-04 | -0.80 |
| 2026-02-03 | -0.82 |
| 2026-02-02 | -0.82 |
| 2026-01-30 | -0.77 |
| 2026-01-29 | -0.75 |
| 2026-01-28 | -0.69 |
| 2026-01-27 | -0.69 |
| 2026-01-26 | -0.68 |
| 2026-01-23 | -0.68 |
| 2026-01-22 | -0.71 |
| 2026-01-21 | -0.68 |
| 2026-01-20 | -0.68 |
| 2026-01-16 | -0.68 |
| 2026-01-15 | -0.73 |
| 2026-01-14 | -0.78 |
| 2026-01-13 | -0.75 |
| 2026-01-12 | -0.70 |
| 2026-01-09 | -0.71 |
| 2026-01-08 | -0.75 |
| 2026-01-07 | -0.80 |